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The CD14 (−159 C/T) SNP is 
associated with sCD14 levels and 
allergic asthma, but not with CD14 
expression on monocytes
J. J. Nieto-Fontarigo1, F. J. Salgado1, M. E. San-José2, M. J. Cruz3,4, A. Casas-Fernández2,  
M. J. Gómez-Conde2, L. Valdés-Cuadrado5,6,7, M. Á. García-González6, P. Arias1, M. Nogueira1 
& F. J. González-Barcala  4,5,6,7
LPS-ligation to CD14/TLR-4 on monocytes/macrophages triggers the production of IL-12-family 
cytokines. IL12/18 promote TH1-differentiation, counteracting the TH2-driven asthma. Therefore, CD14 
modulation could alter the TH2-differentiation and should be taken into account when studying asthma. 
To analyse the alteration in CD14 levels and its association with CD14 (−159 C/T) SNP (rs2569190) 
in Caucasian adults with stable allergic asthma, we performed a cross-sectional study (277 healthy 
subjects vs. 277 patients) where clinical parameters, CD14 values and the CD14 (−159 C/T) SNP were 
studied. Apart from typical biomarkers, we found an increment of neuron-specific enolase (NSE) in 
allergic asthma, probably linked to monocyte activity. Indeed, we evidenced increased monocyte 
numbers, but lower CD14 expression and normalised sCD14 values in patients. Moreover, we noticed an 
association of the T allele (P = 0.0162) and TT genotype (P = 0.0196) of the CD14 SNP with a decreased 
risk of allergic asthma and augmented sCD14 levels. In conclusion, monocyte CD14 expression and 
normalized sCD14 values were reduced in stable state asthmatics, and this could be related to the 
presence of an expanded CD14low monocyte subset. This study also demonstrates that the CD14 (−159 
C/T) polymorphism is a risk factor for moderate-severe allergic asthma in adult Caucasians.
During asthma attacks allergens trigger lung epithelial cells to release cytokines (e.g., Thymic stromal lym-
phopoietin (TSLP), Interleukin (IL)-33, IL-25) that activate innate leukocytes and drive the differentiation 
of allergen-specific T helper (TH)2 lymphocytes1. Innate defences also rely on pattern recognition receptors, 
such as toll-like receptors (TLRs), capable of detecting pathogen-associated molecular patterns (PAMPs). 
Lipopolysaccharide (LPS) is a PAMP that interacts with CD14 (monocytes, macrophages, and neutrophils)2, a 
receptor whose gene has been linked to asthma/allergy3. CD14 transfers LPS to the TLR4-MD2 complex, which 
induces the secretion of a set of cytokines (IL-12/IL-18) that act as an innate-adaptive bridge and favour the TH1 
differentiation4. In addition, IL-12 also prevents the development of allergen-specific TH2 cells, which ameliorates 
airway inflammation in allergic asthma4. Therefore, a functional defect in CD14 could alter TH2 differentiation 
and IgE-mediated allergic diseases5.
Membrane-bound CD14 (mCD14) is released to the medium as soluble CD14 (sCD14)2,6,7, which either 
potentiates the response to LPS in macrophages by inducing the release of proinflammatory cytokines8, or has 
a protective role by transferring LPS to lipoproteins9. sCD14 is released from monocytes through a process 
enhanced by LPS, IL-6 and IL-1β6, but decreased by interferon-γ (IFN-γ) and IL-410. sCD14 inversely correlates 
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with IL-411, but positively with the number of sputum eosinophils12. Moreover, plasma sCD14 is a biomarker of 
ongoing or acute immune responses2,13. Thus, children with asthma exacerbations display augmented sCD14 
levels compared to the recovery phase14,15, whereas adult asthmatics have higher amounts in sputum than healthy 
subjects12. An increased sCD14 concentration has also been detected in bronchoalveolar lavage fluid (BALF) 
upon allergen exposure16. However, other works reported unaltered sCD14 levels, like for example in asthmatic 
children7,15.
Single-nucleotide polymorphisms (SNPs) also constitute modulatory agents for CD14 levels that could influ-
ence the risk factors for developing asthma or aggravate disease symptoms17. Baldini et al. found an association 
between CD14 (−159 C/T) SNP (rs2569190) and sCD14 in atopic children, showing TT homozygotes higher 
levels than CT/CC genotypes11 in line with the enhanced CD14 transcriptional activity in the T allele5. Since those 
landmark studies, different works have confirmed these results18,19, while the C allele has been associated with 
high IgE levels, atopy and asthma15,17,20. However, this association has not been consistently replicated3,13,21–24. 
These different results may be attributed to a number of factors, like the low sample size, asthma phenotype 
(atopic, non-atopic or mixed asthma), age of study population (children or adults), ethnicity (African, Caucasian 
or Asiatic population) or gene-environment interactions (e.g., endotoxin levels)21,25. Therefore, it seems necessary 
to undertake new works aimed to the simultaneous measurement of both membrane and soluble forms of CD14 
as well as the CD14 (−159 C/T) SNP in adult Caucasian subjects with allergic asthma and different degrees of 
severity (intermittent-mild and moderate-severe).
Results
Demographic and clinical characteristics of the study population. In this work a case-control 
study was performed, where adult patients with both intermittent-mild and moderate-severe allergic asthma 
were recruited. These patients were in a clinically stable state, had a well controlled disease, and the majority were 
non-smokers under treatment with inhaled corticosteroids (Table 1). FEV1 (%) and FEV1/FVC ratio (%) values 
are described in Table 1, showing decreased levels in MSAA (moderate-severe allergic asthmatics) compared to 
IMAA (intermittent-mild allergic asthmatics) (Table 1). Although 66.4% of AA came from rural areas, most of 
them had no animals or just dogs/cats; only 11% were taking care of farm animals.
According to their allergic disease state, patients had significantly augmented levels of eosinophils and total 
IgE compared to HC, but there were no significant changes regarding disease severity (Table 1). IgE showed a 
positive correlation with eosinophil, monocyte and, to a lesser extent, lymphocyte blood count, underlying the 
relevance of these subsets in allergic asthma pathogenesis (Table 2). Since activation of eosinophils and mac-
rophages has been associated to enhanced NSE levels under some pathological conditions26,27, we also undertook 
the measurement of this enzyme in serum samples. As Table 2 shows, it was found a positive correlation of IgE, 
eosinophils and monocytes with NSE (Table 2), which prompted us to examine the utility of this parameter as an 
additional marker of allergic asthma. As shown in Fig. 1a, NSE levels were augmented in AA compared to HC 
and tend to be around 14.6% higher in men than in women (Fig. 1a). Moreover, the area under the curve (AUC) 
of the ROC plot for NSE levels was close to AUC of total IgE and higher than AUC of blood eosinophils (absolute 
values) (Fig. 1b).
No alterations were appreciated for C-reactive protein (CRP), IgG, IgA, IgM, or tumour necrosis factor (TNF) 
in AA. The influence of age was also taken into consideration, with a negative correlation with FEV1%, FEV1/
FVC, IgE and leukocyte subtypes (mostly eosinophils), but a small positive association with TNF, CRP, mCD14 
and sCD14 (Table 2).
Allergic asthma enhances the number of peripheral blood monocytes, but causes a reduction 
of mCD14 in these cells. Complete blood count revealed an increased number of leukocytes in AA (HC 
6.44 (5.39–7.75) × 103 cells/μL vs. AA 6.93 (6.00–8.23) × 103 cells/μL; P < 0.001). These differences were partially 
dependent on some innate subsets like eosinophils and monocytes, but not neutrophils or basophils (Table 1). 
Moreover, men had higher numbers of monocytes in peripheral blood than women (P < 0.0001), and asthma 
caused a slight but significant elevation of monocytes in both IMAA and MSAA (Fig. 2a). mCD14 was mainly 
expressed by monocytes (>90% CD14+) (Supplementary Figure 1), and asthma produced a decrease in the per-
centage of CD14+ monocytes (and mean fluorescence intensity/MFI values), without changes between IMAA and 
MSAA (Fig. 2b and c). Indeed, when a ROC curve was constructed for mCD14 values (%), the AUC gave a value 
of 0.7881 (whole asthmatics), which underlines the potential use of this parameter as an allergic asthma marker 
(Fig. 2d), even after segregating the patients in IMAA and MSAA.
Apart from monocytes, neutrophils and lymphocytes also contain CD14+ cells, but the expression of this 
marker is much lower than in monocytes (Supplementary Figure 1). Because of this, we assessed the differences 
between neutrophils and lymphocytes-associated mCD14 levels in AA and HC, but they were not influenced by 
the presence of allergic asthma (data not shown).
Reduction of relative but not absolute sCD14 levels in allergic asthma. Despite the decreased 
levels of mCD14 in monocytes from AA, we did not reach significant differences in the serum concentration 
of sCD14 in IMAA, MSAA and HC (data not shown). Moreover, when a cut-off value of total IgE (80 IU/mL) 
was selected to maximize the true positive rate (70.76%) and minimize the false positive rate (15.88%) (Fig. 1b), 
sCD14 levels remained unaltered in donors with IgE < 80 IU/mL or ≥80 IU/mL.
As our results were supporting the presence of altered numbers of monocytes in asthmatic patients, and 
monocytes were the most likely source of sCD14, we evaluated the correlation between the absolute count of 
peripheral blood monocytes and the serum concentration of sCD14, with negative results (Table 2). In spite of 
this, sCD14 levels could still be influenced by the combined effects of increased monocyte count and decreased 
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expression of mCD14 on this leukocyte subset (phenotype). Accordingly, sCD14 values were normalised with 
respect to the absolute number of circulating monocytes to maximize the effect of cell phenotype, finding in this 
case a significant reduction of sCD14 in AA compared to HC even after segregating by disease severity (Fig. 2e). 
We also detected higher levels of relative sCD14 in women compared to men (data not shown).
We next examined the mCD14-sCD14 correlation. In order to analyse the strength of this relationship, we 
have taken into account the absolute and normalized values of sCD14, as well as we have analysed the data as a 
whole or after segregating our results according to sex or donor group (healthy or diseased). However, we have 
found no connection between both parameters (Table 2, whole set of mCD14-sCD14 pairs), which underlines 
an independent regulation of both molecules. Apart from the monocyte count, alternative reasons might explain 
this low correlation, like other sCD14 sources (e.g. hepatocytes) or the existence of different genetic backgrounds. 
Regarding the first possibility, there were no differences in CRP or TNF between HC and AA (P > 0.05), or 
evidence of respiratory infection, even though there is very small correlation between CRP or TNF and sCD14 
(Table 2). Therefore, we next analysed the influence of the CD14 (−159 C/T) SNP genotype (rs2569190) on 
mCD14/sCD14 levels.
Genotypic and allelic frequency distribution of CD14 (−159 C/T) SNP in the study popula-
tion. Genotype (TT, TC, CC) and allelic (C, T) frequencies were calculated in this study, and their distribution 
presented in Table 3. The whole population (χ2 = 0.014, P > 0.05), HC (χ2 = 0.002, P > 0.05), AA (χ2 = 0.007, 
P > 0.05), IMAA (χ2 = 0.041, P > 0.05), and MSAA (χ2 = 0.012, P > 0.05) were in HWE. Moreover, there was 
association between the (−159 C/T) SNP and the presence of asthma (Table 3), showing a decrease in the fre-
quency of the T allele in AA (P = 0.016) and MSAA (P = 0.013), but not in IMAA compared to HC. Furthermore, 
the frequency of TT genotype of CD14 polymorphism were significantly lower in AA than in HC (P = 0.049), 
being only significant in MSAA (P = 0.039) when patients were segregated according to disease severity (Table 3).
As allelic and genotypic frequencies seem to be related to disease severity, we further divide MSAA into mod-
erate (N = 129) and severe allergic asthmatics (N = 40). After this segregation, the association of the (−159 C/T) 
SNP was only maintained in severe asthmatics, both the allelic (T vs. C, χ2 = 6.478, P = 0.011) and genotypic (TT 
vs. CC, χ2 = 7.429, P = 0.024) frequencies, and it was lost in moderate asthmatics (T vs. C, χ2 = 2.749, P = 0.097; 
TT vs. CC, χ2 = 3.040, P = 0.219).
Association between CD14 (−159 C/T) SNP and allergic asthma risk. A summary of allergic 
asthma risk according to the different genetic models is presented in Table 4. We found an association between 
T allele and a decreased allergic asthma risk in the overall allergic asthma population (T vs. C: OR = 0.74, 95% 
CI = 0.59–0.94, P = 0.0162). Moreover, when AA were subset by disease severity (IMAA and MSAA vs. HC), this 
AA
HCALL IMAA MSAA
N 277 108 169 277
Agea 32 (25–42) 31 (22–38) 33 (26–46) 46 (31–60)
Sex (M/F) 119/158 42/66 77/92 105/172
Smokers (%) 21.3 15.7 24.8 0
Control
 Good 219 98 121 —
 Partial 36 8 28 —
 Bad 22 2 20 —
Treatment:
 No 66 66 0 —
 Inhaled Corticosteroids 196 34 162 —
 Oral Corticosteroids 15 0 15 —
 Antileukotrienes 63 6 57 —
 Omalizumab 4 0 4 —
FEV1 (%) 97.2 (83.7–108.0) 105.0 (95.3–115.7)# 93 (74.5–102.2)# —
FEV1/FVC (%) 78.0 (70.7–85.4) 82.9 (75.9–88.4)# 74.7 (67.6–81.9)# —
Neutrophils (103 cells/μL)a 3.67 (2.77–4.50) 3.53 (2.99–4.27) 3.71 (2.90–4.96) 3.54 (2.77–4.50)
Lymphocytes (103 cells/μL)a 2.22 (1.85–2.71)* 2.20 (1.86–2.79)& 2.23 (1.80–2.71)& 2.02 (1.62–2.45)
Monocytes (103 cells/μL)a 0.47 (0.38–0.59)* 0.47 (0.39–0.56)& 0.46 (0.37–0.62)& 0.35 (0.28–0.43)
Eosinophils (103 cells/μL)a 0.33 (0.19–0.51)* 0.29 (0.20–0.51)& 0.34 (0.18–0.51)& 0.16 (0.11–0.23)
Basophils ((103 cells/μL)a 0.04 (0.03–0.05) 0.04 (0.03–0.05) 0.04 (0.02–0.06) 0.04 (0.03–0.06)
IgE (IU/mL)a 272 (116–533)* 270 (111–485)& 276 (122–668)& 34 (11–102)
Table 1. Characteristics of the study population. AA, allergic asthmatics; HC, healthy controls; IMAA, 
intermittent-mild allergic asthmatics; MSAA, moderate-severe allergic asthmatics. aMedian value (IQR1–3); 
*AA vs HC: Mann-Witney U Statistic, P < 0.001; #IMAA vs MSAA: Mann-Witney U Statistic, P < 0.001; 
&IMAA vs MSAA vs HC: Kruskal-Wallis One Way Analysis of Variance on Ranks (P < 0.001), IMAA/MSAA vs 
HC P < 0.05 Dunn’s Method.
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association was maintained only for MSAA (OR = 0.70, 95% CI = 0.54–0.92, P = 0.0136), while IMAA lost the 
allelic association (Table 4).
Regarding to the other genetic models, a significant association of CD14 (−159 C/T) and allergic asthma risk 
was found between the homozygotes TT vs. CC (OR = 0.55, 95% CI = 0.34–0.89, P = 0.0196), and almost reached 
significance in a dominant model (TT + TC vs. CC: OR = 0.67, 95% CI = 0.45–0.98, P = 0.0511) (Table 4). 
Furthermore, after segregating by disease severity, it was found an association of allergic asthma risk with this 
SNP only in MSAA according to a recessive model (TT vs. TC + CC: OR = 0.61, 95% CI = 0.38–0.96, P = 0.0442) 
or TT vs. CC genotype comparisons (OR = 0.49, 95% CI = 0.28–0.85, P = 0.0163). Therefore, the results suggested 
that T allele and TT homozygote individuals have decreased risk of allergic asthma compared with C allele and 
CC homozygote carriers, respectively.
The influence of the CD14 (−159 C/T) SNP on CD14 levels. Although we have shown augmented 
peripheral blood monocyte count and decreased levels of mCD14 (Fig. 2a–c), the number of monocytes was not 
influenced by the CD14 (−159 C/T) SNP genotype. We also failed to detect any change in mCD14 related to the 
SNP genotype (data not shown). In contrast (and regardless of whether they belong to the control group or to 
the asthmatic population), CC genotypes and to a lesser extent TC genotypes had lower concentrations of sCD14 
(absolute values) than TT carriers, while no significant differences were observed between TC and CC subjects 
(Fig. 3a). This association was maintained between TT and CC carriers when sCD14 levels where normalised by 
the absolute count of monocytes (Fig. 3b). Therefore, this SNP could be partially responsible for the reduction of 
normalised sCD14 levels in AA and influence the severity of this disease (Fig. 2e).
VARIABLES NSE CRP IgE mCD14# sCD14 Age
Leucocyte count 0.163* 0.221*** 0.192*** −0.021 −0.035 −0.165***
Neutrophil count 0.003 0.190*** −0.027 −0.027 −0.034 −0.052
Lymphocyte count 0.077 0.107* 0.143*** −0.020 −0091 −0.152***
Monocyte count 0.303*** 0.154*** 0.336*** 0.234***P −0.021 −0.182***
Eosinophil count 0.279*** 0.054 0.459*** −0.199*** −0.071 −0.273***
Basophil count 0.149*** −0.024 0.057 −0.034 −0.005 −0.113*
FEV1% 0.099 P −0.088 P −0.057 P 0.140 P −0.177 P −0.209***P
FEV1/FVC 0.106 P −0.071 P −0.051 P 0.151 −0.146 P −0.375***P
TNF −0.022 0.179*** −0.011 0.082 0.119** 0.198***
NSE −0.004 0.322*** −0.215*** 0.087 −0.128**
CRP −0.033 −0.000 0.158*** 0.119**
IgE −0.264*** −0.054 −0.296***
mCD14# −0.079 0.177***
sCD14 0.102*
Table 2. Spearman correlation matrix of the study population. CRP, C-reactive protein; IgE, immunoglobulin 
E; NSE, neuron specific enolase; P, patient population; TNF, tumour necrosis factor. *P < 0.05, **P < 0.01, 
***P < 0.001. #% of CD14+ monocytes.
Figure 1. Analysis of NSE values in serum from AA and HC. (a) NSE levels in allergic asthmatics (AA) and 
healthy controls (HC) segregated by gender. Numbers on the graphs represent P-values (Mann-Whitney U test). 
(b) ROC curves for IgE, NSE and peripheral blood eosinophils. AUC values are shown for each parameter.
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Discussion
In the current study, we report data supporting an increase of NSE and monocytes and a down-modulation of 
their mCD14 expression in allergic asthma regardless of disease severity. In addition, we detect a decrease of 
Figure 2. Monocyte count and mCD14/sCD14 levels in AA and HC. (a) Peripheral blood monocyte count 
in IMAA, MSAA and HC. Percentage of CD14+ cells (b) and mean fluorescence intensity (MFI) of CD14 on 
monocytes (c) in IMAA, MSAA and HC. (d) ROC curve for the percentage of CD14+ monocytes. (e) Relative 
sCD14 levels (ng/1 × 103 monocytes) in serum samples from IMAA, MSAA and HC. Numbers on the graphs 
represent P-values (Mann-Whitney U test).
N
Genotype frequencies (%) Allele frequencies (%)
TT TC CC T C
HC 277 79 (28.5) 138 (49.8) 60 (21.7) 296 (53.4) 258 (46.6)
AA 277 59 (21.3) 137 (49.5) 81 (29.2) χ2 = 6.030 P = 0.049* 255 (46.0) 299 (54.0) χ2 = 5.776a P = 0.016*
IMAA 108 26 (24.1) 52 (48.1) 30 (27.8) χ2 = 1.851 P = 0.3963 104 (48.1) 112 (51.9) χ2 = 1.531a P = 0.2159
MSAA 169 33 (19.5) 85 (50.3) 51 (30.2) χ2 = 6.444 P = 0.039* 151 (44.7) 187 (55.3) χ2 = 6.091a P = 0.013*
Table 3. Genotype and allele frequencies of the CD14 (−159 C/T) SNP in the study population. AA, allergic 
asthmatics; HC, healthy controls; IMAA, intermittent-mild allergic asthmatics; MSAA, moderate-severe allergic 
asthmatics. aYates correction. *Significant difference.
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normalised sCD14 values in serum samples from asthmatics, suggesting the expansion of a CD14low monocyte 
subset and the influence of the CD14 (−159 C/T) SNP genotype. Indeed, we evidence an association of the T 
allele and TT genotype of CD14 (−159 C/T) polymorphism with reduced risk of moderate-severe allergic asthma.
AA in our study have an atopic disease with eosinophilia, monocytosis and elevated levels of IgE and NSE. 
NSE is the neuronal isomer of the glycolytic enzyme 2-phospho-D-glycerate hydrolase, and a typical biomarker 
of small cell lung cancer28. Nevertheless, changes in non-malignant inflammatory lung diseases have also been 
found27,29–32, since this enzyme can translocate towards the cell surface upon proper stimulatory signals to 
enhance a proinflammatory response33. Our results support the presence of higher NSE levels in men, as previ-
ously reported by Collazos et al.29, but contrary to this work our asthma patient cohort displays above-normal 
NSE levels in serum. Monocytes/macrophages appear to be a possible source of NSE27,33, and increased numbers 
of monocytes as well as a correlation of them with NSE levels were demonstrated in our study. However, other 
plausible sources of NSE are eosinophils or injured epithelial cells during pulmonary infiltration26, while the neu-
ronal distress or hypoxia occurring in the lung also could play a role during the disease29.
Apart from other cells as T and B lymphocytes, eosinophils, basophils or neutrophils, monocytes are gaining 
importance as regulators of inflammation in asthma and as key players in the pathogenesis34–36. Our results show 
the expansion of this subset in AA regardless the severity of the symptoms (i.e., IMAA and MSAA), as well as 
a reduction of mCD14, a monocyte marker associated to asthma3. In contrast, some authors have described no 
differences in the staining for mCD1437,38, even though these could be the result of a low statistical sample size. 
Reduced levels of mCD14 or TLR4 in AA makes biological sense39, as signal transduction through CD14/TLR4 
leads to IL-12 secretion, a powerful inducer of TH1 polarization13. Therefore, attenuated mCD14 levels on anti-
gen presenting cells (APCs) could favour TH2-driven allergic asthma4,5,13,16. This diminished number of mCD14 
molecules on monocytes could arise as a result of several, and not mutually exclusive, mechanisms: (a) altered 
transcription/translation rates affecting protein abundance; (b) expansion of CD14low monocyte subsets; (c) a 
vesicle- or enzymatic-mediated mechanism that release mCD14 from monocytes and should also affect sCD14 
concentration.
The degree of mCD14 down-modulation on monocytes suggests the preferential expansion of a small CD14low 
subset and not a globally altered transcription/translation rate. This, for example, is in line with the increased 
percentage of CD14−/low monocytes upon in vitro culture in the presence of TSLP, an important cytokine in 
allergic asthma40. Monocytes are heterogeneous, with major (CD14high) and minor (CD14low) subsets32. CD14high 
(“classical”) monocytes display a CD16/FcγRIII- phenotype, while the less frequent CD16+ subset consists of both 
intermediate (CD14highCD16+) and non-classical (CD14lowCD16+) subpopulations33. CD16+ monocytes, par-
ticularly the intermediate subset, are expanded in inflammation, severe asthma or upon allergen challenge33,35, in 
line with their pro-inflammatory nature41. A major constraint of our study is that we have not analysed CD16, but 
our results show a significant down-modulation of mCD14 in allergic asthma, which appears to rather support 
the expansion of CD14lowCD16+ monocytes. These cells (non-classical subset) express high levels of CD80, CD86, 
and CD163, suggesting a high antigen presenting capability42. Furthermore, non-classical monocytes are in an 
advanced differentiation stage and they evidence high invading ability to infiltrate and differentiate into M2-type 
macrophages43, a subset related to allergic inflammation44.
CD14 can be released to medium from hepatocytes as an acute phase protein45. Although we saw a small 
correlation between sCD14 and CRP or TNF, the levels of these two last molecules had no changes between AA 
and HC, and our patients were in a steady-state of the disease. Excluding the hepatocyte origin, monocytes are 
the most likely cell source of sCD14. Down-modulation of mCD14 in monocytes from AA does not fit with either 
OR (95% CI) χ2 (Yate’s correction) P
AA (ALL)
TT + TC vs CC 0.67 (0.45–0.98)* 3.805 0.0511
TT vs TC + CC 0.68 (0.46–1.00) 3.484 0.0620
TT vs CC 0.55 (0.34–0.89)* 5.449 0.0196*
TC vs CC 0.74 (0.49–1.11) 1.180 0.1704
T vs C 0.74 (0.59–0.94)* 5.776 0.0162*
IMAA
TT + TC vs CC 0.72 (0.43–1.20) 1.300 0.2543
TT vs TC + CC 0.79 (0.48–1.33) 0.566 0.4517
TT vs CC 0.66 (0.35–1.23) 1.346 0.2460
TC vs CC 0.75 (0.44–1.30) 0.781 0.3768
T vs C 0.81 (0.59–1.11) 1.531 0.2159
MSAA
TT + TC vs CC 0.64 (0.42–0.99)* 3.630 0.0547
TT vs TC + CC 0.61 (0.38–0.96)* 4.029 0.0442*
TT vs CC 0.49 (0.28–0.85)* 5.767 0.0163*
TC vs CC 0.72 (0.46–1.15) 1.572 0.2100
T vs C 0.70 (0.54–0.92)* 6.091 0.0136*
Table 4. Association between CD14 (−159 C/T) SNP and allergic asthma risk. AA, allergic asthmatics; CI, 
confidence interval; IMAA, intermittent-mild allergic asthmatics; MSAA, moderate-severe allergic asthmatics; 
OR, odds ratio; TC vs CC, heterozygote; TT vs CC, homozygote; TT vs TC + CC, recessive model; TT + TC vs 
CC, dominant model. *Significant difference.
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its shedding2,6,7 or the release of mCD14-enriched vesicles [http://exocarta.org/gene_summary?gene_id=12475] 
from these cells, because both processes should lead to a higher number of sCD14 molecules in the extracellular 
compartment, as happen during the acute phase15,16,46,47. However, patients in our study are in a chronic phase, 
where there is no relationship between monocyte count and sCD14 or mCD14-sCD14 correlation16. Therefore, 
our results only make sense considering a puzzling scenery with an elevation of monocyte numbers and enhanced 
frequencies of both CD14high 34, but also CD14low (our results) subsets of monocytes in asthma. Indeed, in our 
study only normalised serum levels of sCD14 were significantly reduced in patients. In agreement, sCD14 levels 
have been inversely correlated with IL-4-production11, total IgE11, or asthma severity46. However, some authors 
have detected higher levels12 or no differences7,15 of baseline sCD14 in peripheral blood from asthmatics. Hence, 
we cannot rule out the contribution of many potential confounding factors that explain these different results, like 
gene-gene or gene-environment interactions11,15.
One of the most studied CD14 polymorphisms in asthma is the CD14 (−159 C/T) SNP (rs2569190)11. 
Previous studies investigating the association of this SNP with allergic asthma yielded variable results regarding 
to the strength and direction of association3,17,24. These contradictory results can be explained by differences in 
ethnicity, low sample size, age of patients or gene-environment interaction21,25. We performed our study in a 
well-defined population (Caucasian, adults, allergic asthmatics and mostly non-farmers), with a high sample size 
(277 AA vs. 277 HC), and two different disease severity grades (IMAA and MSAA). In agreement with others11,17, 
we show an association of the frequency of the C allele and the CC genotype with allergic asthma (whole asthmat-
ics). More interesting, this association is also related to the disease severity, as it is only maintained in MSAA and, 
within this group, in severe asthmatics. Moreover, the risk of having moderate-severe allergic asthma (but not 
intermittent-mild asthma) is lower in carriers of the T allele (T vs. C) and TT genotype, following either a reces-
sive model (TT vs. TC + CC) or after comparing TT vs. CC homozygotes. As other works have shown5,11,12,18,19, 
we evidence augmented sCD14 levels in subjects carrying the TT genotype but no association of this polymor-
phism with mCD14 levels on monocytes. This suggests an adverse role for the C allele, the CC genotype and 
the presence of low levels of sCD14/mCD14 in allergic asthma or atopy11,46, especially among adult and atopic 
subjects exposed to low levels of endotoxin, like our cohort13.
In summary, our findings show an increment in the serum levels of NSE, which could be used as a novel 
biomarker of allergic asthma. On the other hand, we also found a decrease in the expression of CD14 on mono-
cytes from allergic asthmatic patients, probably related to an increase of CD14low monocyte subset. Moreover, we 
evidence an association of the (−159 C/T) SNP in the CD14 promoter with allergic asthma, and a decreased risk 
of having moderate-severe allergic asthma in carriers of T allele and TT genotype. Furthermore, TT genotype is 
associated to higher levels of sCD14, pointing out a protective role for the T allele in this disease.
Methods
Subjects. The study population was recruited from January 2009 to December 2012, at the Unit of 
Pneumology and Allergy of the USC University Hospital Complex of Santiago de Compostela (CHUS) and 
the Pontevedra Hospital Complex (CHOP). This study population included 277 healthy controls (HC) and 277 
allergic asthmatics (AA), consisting of 108 intermittent-mild allergic asthmatics (IMAA) and 169 moderate-se-
vere allergic asthmatics (MSAA). Asthma and allergy diagnosis was confirmed according to Global Strategy 
for Asthma Management and Prevention criteria (GINA 2006, http://www.seicap.es/documentos/archivos/
GINA2006general.pdf). All patients were in a stable phase for at least 4 weeks before the study initiation. Forced 
vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and the FEV1/FVC ratio, were measured. 
Asthma diagnosis was confirmed by a positive broncodilatator test (>12% of FEV1 change after salbutamol) or 
metacholine challenge. Allergic sensitization was confirmed through a skin prick test or serum IgE specific to 
frequent allergens. Other variables were measured: smoking, pets at home, residence (rural/urban), profession, 
comorbidities, age of symptoms onset, asthma control, or number of visits to emergency units, family doctors or 
Figure 3. Impact of the CD14 (−159 C/T) SNP (rs2569190) on sCD14 levels in serum. Absolute (ng/mL) (a) 
and relative (ng/1 × 103 monocytes) (b) sCD14 levels in serum samples from TT, TC and CC donors (healthy 
and asthmatics). *Kruskal-Wallis One Way Analysis of Variance on Ranks, P < 0.001; Dunn’s Method was used 
for multiple comparisons (numbers on the graph represent P-values).
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hospitals during the year prior to the study initiation. HC were selected from patients scheduled in the hospital 
for minor surgeries such as orthopedic surgery or inguinal hernia, and smoking and systemic diseases or aller-
gies were used as exclusion criteria. The research was carried out according to The Code of Ethics of the World 
Medical Association (Declaration of Helsinki). The project was also approved by the Ethics Committee of Clinical 
Research of Galicia (2011/001), Spain, and all subjects signed informed consent statements.
Flow cytometry assays. Venous peripheral blood was collected in ethylenediaminetetraacetic acid 
(EDTA) treated tubes (BD Vacutainer K2E). To analyse the expression of CD14 on peripheral blood leukocytes, 
CD14-FITC (Mouse IgG2a κ; BD Biosciences) or Isotype-FITC (Mouse IgG2a; BD Biosciences) were added to 
100 μL of whole blood (30 min, room temp.). Then, red cells were lysed (BD FACSTM Lysing Solution). Finally, 10 
000 events were collected and analysed by means of a BD FACSCalibur flow cytometer. Data were examined using 
WinMDI 2.9 software (Joseph Trotter, La Jolla, CA. USA).
Biochemical determinations. Biochemical determinations were carried out by an ADVIA®1650 analyser 
(SIEMENS Healthcare Diagnostics S.L., Berlin, Germany) while neuron-specific enolase (NSE) was meas-
ured with electrochemiluminescence analyser (MODULAR ANALYTICS Cobas E-601, Roche Diagnostics; 
Mannheim, Germany). The nucleated cell counting was performed using an ADVIA®2120 hematology counter 
(SIEMENS Healthcare Diagnostics S.L., Berlin, Germany).
Serum sCD14 levels were measured by means of an enzyme-linked immunosorbant assay (ELISA) with the 
Quantikine®Human sCD14 Immunoassay kit (R&D Systems, MN, USA). Optical densities were recorded at 
450 nm and protein concentration was calculated from standard curves.
Genomic DNA purification and CD14 (−159 C/T) promoter SNP (rs2569190) studies. Genomic 
DNA was purified from whole blood (200 µL) with the QIAamp® DNA Mini Kit (QIAGEN, Melbourne, 
Australia). The subsequent study of the rs2569190 SNP in the CD14 promoter was conducted by the 
CEGEN-PRB2 USC node using the iPlex® Gold chemistry and MassARRAY platform, according to manufactur-
er’s instructions (Agena Bioscience, San Diego, CA). Genotyping assay (Polymerase chain reaction/PCR primers 
and single-base-extension/SBE primers) were designed using the Agena Bioscience MassARRAY Assay Designer 
4.1 software. To avoid confusion in the mass spectrum, a tag (5-ACGTTGGATG-3) was added to the 5′ end of 
each PCR primer. Both SBE and PCR primer sequences are shown in Supplementary Table 1. PCR reaction was 
set up in a 5 µL volume and contained of template DNA (20 ng), 1 × PCR buffer, MgCl2 (2 mM), dNTPs (500 µM) 
and PCR enzyme (1 U/reaction). A pool of PCR primers was made at a final concentration of each primer of 
100 nM (Metabion International AG, Germany). The thermal cycling conditions for the reaction consisted of an 
initial denaturation step at 95 °C for 2 minutes, followed by 45 cycles of 95 °C for 30 seconds, 56 °C for 30 seconds 
and 72 °C for 1 minute, and a final extension step of 72 °C for 5 minutes. PCR products were treated with shrimp 
alkaline phosphatase (1.5 U) by incubation at 37 °C for 40 min, followed by enzyme inactivation by heating at 
85 °C for 5 min to neutralize unincorporated dNTPs.
The iPLEX GOLD reactions were set up in a final 9 µL volume and contained 0.222 × iPLEX buffer Plus, 
0.222 × iPLEX termination mix and iPLEX enzyme (1.35 U/reaction). A SBE primer mix was made to give a 
final concentration of each primer between 0.52 µM and 1.57 µM (Metabion International AG, Germany). The 
thermal cycling conditions for the reaction included an initial denaturation step at 95 °C for 30 seconds, followed 
by 40 cycles of 95 °C for 5 seconds, with an internal 5 cycles loop at 52 °C for 5 seconds and 80 °C for 5 seconds, 
followed by a final extension step of 72 °C for 3 minutes. The next step was to desalt the iPLEX Gold reaction 
products with Clean Resin following the manufacturer’s protocol. The desalted products were dispensed onto a 
384 Spectrochip II using an RS1000 Nanodispenser and spectra were acquired using the MA4 mass spectrom-
eter, followed by manual inspection of spectra by trained personnel using MassARRAY Typer software, version 
4.0. All assays were performed in 384-well plates, including negative controls and a trio of Coriell samples 
(Na10830, Na10831 and Na12147) for quality control. 10% random samples were tested in duplicate and the 
reproducibility was 100%.
Statistics. Descriptive data are presented as either median (interquartile range; IQR1–3) or percentages. To 
assess the significance of changes between AA and HC, Mann–Whitney U two-tailed test or Kruskal–Wallis One 
Way Analysis of Variance on Ranks followed by Dunn’s multiple comparison test were used. Receiver Operating 
Characteristic (ROC) curves and Spearman’s association test were also employed, while differences in proportions 
were assayed by the χ2 test. To evaluate the association between CD14 (−159 C/T) SNP and the risk of allergic 
asthma, Odd’s ratios (ORs) and 95% confidence intervals (CIs) were calculated according to different models: 
TT + TC vs. CC (dominant model), TT vs. TC + CC (recessive model), TT vs. CC, TC vs. CC, and T vs. C (allelic 
model). Hardy–Weinberg equilibrium (HWE) was calculated by using Pearson χ2 test. All analyses and graphs 
were conducted using GraphPad Prism version 6.0 (GraphPad Software, Inc., San Jose, California, USA). Data are 
presented in box and whisker plots, where median, 25 and 75 quartiles, 5–95 percentiles (error bars) and anoma-
lous values are shown. The statistical signification was defined as P < 0.05.
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